CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma

Video

This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.

Patients with advanced non-Hodgkin lymphoma have limited options after treatment failure with chemotherapy or transplant.

In this video, Frederick Locke, MD, of the Moffitt Cancer Center in Tampa, Florida, discusses results of the ZUMA-1 trial, which tested chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel; KTE-C19) in this patient population. The treatment is given as a single infusion after conditioning chemotherapy with fludarabine and cyclophosphamide.

The multicenter clinical trial enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. Nearly all (99%) were able to have axi-cel manufactured from their cells. A total of 101 patients (91%) received the CAR T-cell therapy (10 patients were unable to receive therapy after cell collection, most due to disease progression).

Locke highlights the overall and complete response rates in the trial, compares the results to previous data involving other treatments in a similar patient population, and reviews toxicities associated with CAR T-cell therapy.

The results of ZUMA-1, which showed a 6-month overall survival of 80% (compared to 55% for historical controls), were presented at the 2017 American Association for Cancer Research Annual Meeting, held April 1–5 in Washington, DC.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.